Q-omics provides the consensus-scored MTATP6P18 profile across patient tissues and cancer cell-line models. MTATP6P18 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MTATP6P18 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, MTATP6P18 RNA expression shows 8,984 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KICH, and TGCT as cancer lineages where MTATP6P18 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTATP6P18 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTATP6P18 survival associations across molecular data types. MTATP6P18 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTATP6P18 RNA expression–survival associations across cancer types. High MTATP6P18 expression shows unfavorable associations in STAD, LUAD and PAAD, but favorable associations in BLCA, ACC and TGCT. The BLCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .004). Together, the overview and detailed table identify BLCA as the clearest survival context for MTATP6P18 RNA expression.
This table summarizes MTATP6P18 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTATP6P18. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTATP6P18 shows lower tumor expression in BRCA and higher tumor expression in KICH, UCEC and KIRP. The KICH box plot shows higher MTATP6P18 RNA expression in tumor versus normal tissue (log2 FC = +0.181, t-test p = .005).
This table shows molecular features associated with MTATP6P18 in patient tissues and cancer cell lines. In patient samples, MTATP6P18 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
